38 results on '"Driessen, Maurice T."'
Search Results
2. A Dutch cost-effectiveness analysis of fremanezumab versus best supportive care in patients with chronic migraine and inadequate response to prior preventive therapy
3. Real-world Impact of Fremanezumab on Migraine-Related Health Care Resource Utilization in Patients with Comorbidities, Acute Medication Overuse, and/or Unsatisfactory Prior Migraine Preventive Response
4. Burden of Episodic and Chronic Migraine in Patients Who Had Failed Multiple Preventive Treatments From France, Spain, and the United Kingdom.
5. Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study
6. Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine
7. A real-world study of acute and preventive medication use, adherence, and persistence in patients prescribed fremanezumab in the United States
8. Assessment of rituximab-abbs, a biosimilar, and rituximab outcomes in patients with CLL or NHL: A real-world UK study
9. Comment on: Gao B, Lu Q, Wan R, Wang Z, Yang Y, Chen Z, Wang Z. “Monthly versus quarterly fremanezumab for the prevention of migraine: a systemic review and meta-analysis from randomized controlled trials”. Naunyn Schmiedebergs Arch Pharmacol. 2021 Apr;394(4):819–828. Epublished November 2020
10. Clinical Outcomes and Health-Care Resource Use Associated With Reslizumab Treatment in Adults With Severe Eosinophilic Asthma in Real-World Practice
11. Real-World Effectiveness of Add-Onfremanezumab in Patients Receiving OnabotulinumtoxinA for the Prevention of Chronic Migraine in a US Tertiary Headache Center: A Retrospective Chart Review Study
12. Real-world effectiveness of add-on fremanezumab in patients receiving onabotulinumtoxinA for the prevention of chronic migraine in a US tertiary headache center: A retrospective chart review study
13. Systematic review of association between critical errors in inhalation and health outcomes in asthma and COPD
14. Reductions in Migraine-related Health Care Resource Utilization and Costs for Patients Initiating Fremanezumab: Results of a Long-term US Claims Database Analysis (P12-2.002)
15. Reductions in Acute Medication Use for Patients with Migraine Initiating Fremanezumab: Results of a Long-term US Claims Database Analysis (P16-2.005)
16. Participatory ergonomics to reduce exposure to psychosocial and physical risk factors for low back pain and neck pain: results of a cluster randomised controlled trial
17. The effectiveness of participatory ergonomics to prevent low-back and neck pain — results of a cluster randomized controlled trial
18. Authors' response: RCTs of ergonomic interventions
19. The effectiveness of physical and organisational ergonomic interventions on low back pain and neck pain: a systematic review
20. Additional file 3 of Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study
21. Additional file 2 of Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study
22. Additional file 1 of Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study
23. Additional file 1 of Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine
24. Economic Evaluation of Ropinirole Prolonged Release for Treatment of Parkinson’s Disease in The Netherlands
25. Real-world patient characteristics, treatment patterns and costs in relapsing multiple sclerosis patients treated with glatiramer acetate, dimethyl fumarate or teriflunomide in Germany
26. Cost-effectiveness of conservative treatments for neck pain: a systematic review on economic evaluations
27. Real-world overall response rate and other outcomes related to originator and biosimilar rituximabin patients with chronic lymphocytic leukemia or non-Hodgkin’s lymphoma in the United Kingdom.
28. Systematic review of association between critical errors in inhalation and health outcomes in asthma and COPD
29. Long-term cost and utility consequences of short-term clinically important deterioration in patients with chronic obstructive pulmonary disease: results from the TORCH study
30. Process evaluation of a participatory ergonomics programme to prevent low back pain and neck pain among workers
31. What are possible barriers and facilitators to implementation of a Participatory Ergonomics programme?
32. Stay@Work: Participatory Ergonomics to prevent low back and neck pain among workers: design of a randomised controlled trial to evaluate the (cost-)effectiveness
33. Long-term cost and utility consequences of short-term clinically important deterioration in patients with chronic obstructive pulmonary disease: results from the TORCH study
34. Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride
35. Workplace interventions for preventing work disability
36. Stay@Work: Participatory Ergonomics to prevent low back and neck pain among workers: design of a randomised controlled trial to evaluate the (cost-)effectiveness
37. Workplace interventions for preventing work disability
38. Real-world patient characteristics, treatment patterns and costs in relapsing multiple sclerosis patients treated with glatiramer acetate, dimethyl fumarate or teriflunomide in Germany.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.